Literature DB >> 18039833

Intranasal interleukin-12 therapy inhibits Mycoplasma pneumoniae clearance and sustains airway obstruction in murine pneumonia.

C M Salvatore1, M Fonseca-Aten, K Katz-Gaynor, A M Gomez, R D Hardy.   

Abstract

Mycoplasma pneumoniae is a leading cause of pneumonia and is associated with asthma. Evidence links M. pneumoniae respiratory disease severity with interleukin-12 (IL-12) concentrations in respiratory secretions. We evaluated the effects of IL-12 therapy on microbiologic, inflammatory, and pulmonary function indices of M. pneumoniae pneumonia in mice. BALB/c mice were inoculated with M. pneumoniae or SP4 broth. Mice were treated with intranasal IL-12 or placebo daily for 8 days, starting on day 1 after inoculation. Mice were evaluated at baseline and on days 1, 3, 6, and 8 after therapy. Outcome variables included quantitative bronchoalveolar lavage (BAL) M. pneumoniae culture, lung histopathologic score (HPS), BAL cytokine concentrations determined by enzyme-linked immunosorbent assay (tumor necrosis factor alpha [TNF-alpha], gamma interferon [IFN-gamma], IL-1b, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, and granulocyte-macrophage colony-stimulating factor), and plethysmography, both before and after methacholine treatment. M. pneumoniae-infected mice treated with IL-12 (MpIL12 mice) were found to have significantly higher BAL M. pneumoniae concentrations than those of M. pneumoniae-infected mice treated with placebo (MpP mice) (P < 0.001). MpIL12 mice had higher BAL concentrations of IL-12, IFN-gamma, TNF-alpha, and IL-6, with differences in IL-12 and IFN-gamma concentrations reaching statistical significance (P < 0.001). Airway obstruction was statistically elevated in MpIL12 mice compared to that in MpP mice (P = 0.048), while airway hyperreactivity was also elevated in MpIL12 mice but did not reach statistical significance (P = 0.081). Lung parenchymal pneumonia subscores were significantly higher in MpIL12 mice (P < 0.001), but no difference was found for overall HPS, even though a strong trend was noticed (P = 0.051). Treatment of experimental M. pneumoniae pneumonia with intranasal IL-12 was associated with more severe pulmonary disease and less rapid microbiologic and histological resolution.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18039833      PMCID: PMC2223484          DOI: 10.1128/IAI.00878-07

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  46 in total

1.  Definition and application of a histopathological scoring scheme for an animal model of acute Mycoplasma pneumoniae pulmonary infection.

Authors:  N Cimolai; G P Taylor; D Mah; B J Morrison
Journal:  Microbiol Immunol       Date:  1992       Impact factor: 1.955

2.  Expression of pertussis toxin correlates with pathogenesis in Bordetella species.

Authors:  D Monack; J J Munoz; M G Peacock; W J Black; S Falkow
Journal:  J Infect Dis       Date:  1989-02       Impact factor: 5.226

Review 3.  The role of bacterial infections in asthma.

Authors:  M Kraft
Journal:  Clin Chest Med       Date:  2000-06       Impact factor: 2.878

4.  Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor.

Authors:  U Gubler; A O Chua; D S Schoenhaut; C M Dwyer; W McComas; R Motyka; N Nabavi; A G Wolitzky; P M Quinn; P C Familletti
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-15       Impact factor: 11.205

Review 5.  Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes.

Authors:  G Trinchieri
Journal:  Blood       Date:  1994-12-15       Impact factor: 22.113

6.  Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells.

Authors:  A S Stern; F J Podlaski; J D Hulmes; Y C Pan; P M Quinn; A G Wolitzky; P C Familletti; D L Stremlo; T Truitt; R Chizzonite
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

7.  Elevated cytokine and chemokine levels and prolonged pulmonary airflow resistance in a murine Mycoplasma pneumoniae pneumonia model: a microbiologic, histologic, immunologic, and respiratory plethysmographic profile.

Authors:  R D Hardy; H S Jafri; K Olsen; M Wordemann; J Hatfield; B B Rogers; P Patel; L Duffy; G Cassell; G H McCracken; O Ramilo
Journal:  Infect Immun       Date:  2001-06       Impact factor: 3.441

8.  Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production.

Authors:  C L Nastala; H D Edington; T G McKinney; H Tahara; M A Nalesnik; M J Brunda; M K Gately; S F Wolf; R D Schreiber; W J Storkus
Journal:  J Immunol       Date:  1994-08-15       Impact factor: 5.422

9.  Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes.

Authors:  M Kobayashi; L Fitz; M Ryan; R M Hewick; S C Clark; S Chan; R Loudon; F Sherman; B Perussia; G Trinchieri
Journal:  J Exp Med       Date:  1989-09-01       Impact factor: 14.307

10.  Antitumor and antimetastatic activity of interleukin 12 against murine tumors.

Authors:  M J Brunda; L Luistro; R R Warrier; R B Wright; B R Hubbard; M Murphy; S F Wolf; M K Gately
Journal:  J Exp Med       Date:  1993-10-01       Impact factor: 14.307

View more
  9 in total

1.  Variation in colonization, ADP-ribosylating and vacuolating cytotoxin, and pulmonary disease severity among mycoplasma pneumoniae strains.

Authors:  Chonnamet Techasaensiri; Claudia Tagliabue; Marianna Cagle; Pooya Iranpour; Kathy Katz; Thirumalai R Kannan; Jacqueline J Coalson; Joel B Baseman; R Doug Hardy
Journal:  Am J Respir Crit Care Med       Date:  2010-05-27       Impact factor: 21.405

2.  Efficacy of increasing dosages of clarithromycin for treatment of experimental Mycoplasma pneumoniae pneumonia.

Authors:  C Tagliabue; C Techasaensiri; J P Torres; K Katz; C Meek; T R Kannan; J J Coalson; S Esposito; N Principi; R Leff; J B Baseman; R D Hardy
Journal:  J Antimicrob Chemother       Date:  2011-07-25       Impact factor: 5.790

3.  Mycoplasma pneumoniae extract induces an IL-17-associated inflammatory reaction in murine lung: implication for mycoplasmal pneumonia.

Authors:  Daisuke Kurai; Kazuhide Nakagaki; Hiroo Wada; Takeshi Saraya; Shigeru Kamiya; Yasunori Fujioka; Koh Nakata; Hajime Takizawa; Hajime Goto
Journal:  Inflammation       Date:  2013-04       Impact factor: 4.092

4.  Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia.

Authors:  C M Salvatore; C Techasaensiri; C Tagliabue; K Katz; N Leos; A M Gomez; G H McCracken; R D Hardy
Journal:  Antimicrob Agents Chemother       Date:  2009-01-12       Impact factor: 5.191

5.  The impact of steroids given with macrolide therapy on experimental Mycoplasma pneumoniae respiratory infection.

Authors:  C Tagliabue; C M Salvatore; C Techasaensiri; A Mejias; J P Torres; K Katz; A M Gomez; S Esposito; N Principi; R D Hardy
Journal:  J Infect Dis       Date:  2008-10-15       Impact factor: 5.226

Review 6.  Novel aspects on the pathogenesis of Mycoplasma pneumoniae pneumonia and therapeutic implications.

Authors:  Takeshi Saraya; Daisuke Kurai; Kazuhide Nakagaki; Yoshiko Sasaki; Shoichi Niwa; Hiroyuki Tsukagoshi; Hiroki Nunokawa; Kosuke Ohkuma; Naoki Tsujimoto; Susumu Hirao; Hiroo Wada; Haruyuki Ishii; Koh Nakata; Hirokazu Kimura; Kunihisa Kozawa; Hajime Takizawa; Hajime Goto
Journal:  Front Microbiol       Date:  2014-08-11       Impact factor: 5.640

7.  Decreased Interleukin-10 Responses in Children with Severe Mycoplasma pneumoniae Pneumonia.

Authors:  Shenggang Ding; Xiaowu Wang; Wei Chen; Yuan Fang; Boyu Liu; Yan Liu; Guanghe Fei; Linding Wang
Journal:  PLoS One       Date:  2016-01-11       Impact factor: 3.240

8.  Neutrophil-Mediated Lung Injury Both via TLR2-Dependent Production of IL-1α and IL-12 p40, and TLR2-Independent CARDS Toxin after Mycoplasma pneumoniae Infection in Mice.

Authors:  Shigeyuki Tamiya; Eisuke Yoshikawa; Monami Ogura; Etsushi Kuroda; Koichiro Suzuki; Yasuo Yoshioka
Journal:  Microbiol Spectr       Date:  2021-12-22

9.  Analysis of pulmonary inflammation and function in the mouse and baboon after exposure to Mycoplasma pneumoniae CARDS toxin.

Authors:  R Doug Hardy; Jacqueline J Coalson; Jay Peters; Adriana Chaparro; Chonnamet Techasaensiri; Angelene M Cantwell; T R Kannan; Joel B Baseman; Peter H Dube
Journal:  PLoS One       Date:  2009-10-27       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.